期刊
NATURE REVIEWS DRUG DISCOVERY
卷 13, 期 12, 页码 928-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4281
关键词
-
资金
- Harry J.Lloyd Charitable Trust
- Tisch Cancer Institute Developmental Award
- CY14 Developmental Research Pilot Project Program [CY14]
- TCI Young Cancer Research Award
- Career Development Award by the Dermatology Foundation
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据